Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival AnalysisHajime Uno, L. J. Wei, Hicham Skali et al.|Journal of Clinical Oncology|2014Cited by 777
Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and ShadowsMaria Chianese, Barbara Ruaro, Gianluca Screm et al.|Pharmaceuticals|2024Cited by 86
Nailfold Video-Capillaroscopy in Sarcoidosis: New Perspectives and ChallengesMaria Chianese, Barbara Ruaro, Gianluca Screm et al.|Tomography|2024Cited by 7
The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary FibrosisStefano Kette, Barbara Ruaro, Nicolò Reccardini et al.|Pharmaceuticals|2025Cited by 6
Comorbidities’ Effect on IPF: Pathogenesis and ManagementAndrea Salotti, Barbara Ruaro, Maria Chianese et al.|Biomedicines|2025Cited by 3